Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stratec SELTS:0RAR -0.69%72 EV-to-EBITDA is 10.96 as of Aug. 21, 2026, which is 38% below its 10-year median of 17.81. GuruFocus rates LTS:0RAR with a GF Score™ of 72/100 and a GF Value™ of €27.66 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Stratec SE ranks better than 62.79% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Stratec SE's enterprise value is €370.3 Mil.
Stratec SE's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €33.8 Mil. Therefore, Stratec SE's EV-to-EBITDA for today is 10.96.
The historical rank and industry rank for Stratec SE's EV-to-EBITDA or its related term are showing as below:
LTS:0RAR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.78 Med: 17.81 Max: 31.01
Current: 10.96
During the past 13 years, the highest EV-to-EBITDA of Stratec SE was 31.01. The lowest was 4.78. And the median was 17.81.
LTS:0RAR's EV-to-EBITDA is ranked better than 62.79% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.7
vs LTS:0RAR: 10.96
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Stratec SE's share price for today is €21.55.
Stratec SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Stratec SE's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAR vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Stratec SE's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stratec SE EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stratec SE's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Stratec SE's EV-to-EBITDA falls into.
Stratec SE's current Enterprise Value is €370.3 Mil.
Stratec SE's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €33.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stratec SE (LTS:0RAR) has a EV-to-EBITDA of 10.96 as of Aug. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Stratec SE. This is 38% below median its historical median of 17.81. Over the past decade, Stratec SE's EV-to-EBITDA has ranged from 4.78 to 31.01. According to the industry distribution chart, Stratec SE ranks #192 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 37.2%.
Is Stratec SE's EV-to-EBITDA too high?
Stratec SE's current EV-to-EBITDA of 10.96 is 38% below median its 10-year median of 17.81. Over the past 10 years, this metric has ranged from a low of 4.78 to a high of 31.01. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.70. Stratec SE's value of 10.96 is 25.4% below this industry median. Based on the distribution chart, Stratec SE ranks #192 out of 516 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Stratec SE has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stratec SE's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Stratec SE ranks #192 out of 516 companies for EV-to-EBITDA. This puts Stratec SE in the upper half of its industry. The industry median EV-to-EBITDA is 14.70. Stratec SE's value of 10.96 is 25.4% below this benchmark. Historically, Stratec SE's own EV-to-EBITDA has ranged from 4.78 to 31.01 over the past decade. While the company's 10-year median is 17.81 vs. the industry median of 14.70, Stratec SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.70, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stratec SE's current EV-to-EBITDA of 10.96 is 25.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Stratec SE. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stratec SE's current EV-to-EBITDA is 10.96, which is 38% below median its own 10-year median of 17.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stratec SE stock overvalued right now?
Based on GuruFocus' analysis, Stratec SE (LTS:0RAR) is currently considered Modestly Undervalued. The stock's GF Value™ is €27.66, compared to a current price of €21.55 — trading 22.1% below its estimated fair value. The current EV-to-EBITDA is 10.96, which is 38% below median its 10-year median of 17.81 and 25.4% below the Medical Devices & Instruments industry median of 14.70. Stratec SE's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Stratec SE (LTS:0RAR), the current EV-to-EBITDA is 10.96 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stratec SE (LTS:0RAR) Overvalued in 2026?
Based on GuruFocus' analysis, Stratec SE stock appears to be undervalued.
The current stock price of €21.55 is trading 22.1% below its estimated GF Value™ of €27.66.
GuruFocus considers Stratec SE to be Modestly Undervalued.
Key valuation signals for LTS:0RAR:
EV-to-EBITDA: 10.96 (38% below median its 10-year median of 17.81)
GF Value™: €27.66 vs. price of €21.55 (22.1% below fair value)
Industry Position: 25.4% below the Medical Devices & Instruments median (#192 of 516)
No single metric tells the full story. See the LTS:0RAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stratec SE designs and manufactures automation solutions for regulated laboratory markets. STRATEC acts as an OEM partner to players in the in-vitro diagnostics and life sciences markets. The Group's product range includes both hardware solutions, software solutions, and related consumables, as well as independently marketed consumables. These products are mostly combined into fully integrated system solutions and often receive market approval together with partners' reagents.
72GF Score
Get the complete analysis for LTS:0RAR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAR has been successfully added to your 
